Null and Noteworthy: COVID-19 conclusions; diagnosis duplication; oxytocin again
This month’s newsletter explores the pandemic’s effects on autism rates, trends in co-occurring mental health conditions, and the impact of intranasal oxytocin.
Diagnosing autism is an evolving science but a crucial first step to understanding the disorder.
This month’s newsletter explores the pandemic’s effects on autism rates, trends in co-occurring mental health conditions, and the impact of intranasal oxytocin.
Common variants in five regions of the genome may determine whether someone has one condition versus the other.
A standard questionnaire can help identify social (pragmatic) communication disorder more readily in school-age children.
The code may help scientists identify people with the autism-linked condition and recruit them into clinical trials.
Mood, anxiety, personality and eating disorders more commonly affect autistic people diagnosed in adulthood than those diagnosed in childhood.
About 15 percent of genes currently included in clinical genetic tests for autism or intellectual disability don’t have enough evidence to support their ties to the conditions, the panel found.
More than two years into the COVID-19 pandemic, emerging data support the remote tactics that kept autism diagnosis going during lockdowns.
Swiss biotech Stalicla hopes to bring precision medicine to autism. Experts praise efforts to identify autism subgroups, but evidence to support the company’s claims has yet to be seen.
The male sex bias in autism may in large part be a product of how common diagnostic tools measure traits in boys versus girls at a single point in time, according to a new study.
Neurona Health, a company in San Francisco, California, backed away from part of its newly launched services after Spectrum started reporting about them.